Get the Stockscreener App
14.15
0.93%
0.13
After Hours:
14.25
0.10
+0.71%
Keros Therapeutics Inc stock is traded at $14.15, with a volume of 480.22K.
It is up +0.93% in the last 24 hours and down -2.08% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$14.02
Open:
$14.01
24h Volume:
480.22K
Relative Volume:
0.50
Market Cap:
$574.77M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.7583
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
-2.88%
1M Performance:
-2.08%
6M Performance:
-75.49%
1Y Performance:
-69.45%
1-Day Range:
$13.77
$14.32
1-Week Range:
$13.77
$14.91
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.15 | 591.77M | 0 | -168.05M | -146.15M | -5.13 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics' (KROS) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.9%Here's What Happened - MarketBeat
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
D. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Insider Monkey
Janus Henderson Group PLC Has $226,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being - simplywall.st
Keros Therapeutics Shares Drop; Cibotercept Development Halted, Jobs Cut - marketscreener.com
KROS Halts Development of Cibotercept in PAH After Safety Concer - GuruFocus
Keros Therapeutics Announces Corporate Restructuring - citybiz
Keros Therapeutics (KROS) Restructures Focus, Faces Modest Cost Savings | KROS Stock News - GuruFocus
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Benzinga
Keros stock as mid-stage trial for PAH therapy ends (KROS) - Seeking Alpha
Keros Therapeutics, Inc. Announces Corporate Restructuring - marketscreener.com
Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring - marketscreener.com
Keros Therapeutics, Inc. Announces TROPOS Topline Data - marketscreener.com
KROS Announces Workforce Reduction and Strategic Evaluation | KROS Stock News - GuruFocus
Keros Therapeutics halts cibotercept development, plans workforce reduction By Investing.com - Investing.com Canada
Keros Therapeutics halts PAH drug development, cuts workforce - Investing.com
Keros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate Restructuring - Nasdaq
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - Yahoo Finance
1 Stock That Turned $1,000 Into $32 Million - The Globe and Mail
Woodline Partners LP Has $6.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Millennium Management LLC Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Northern Trust Corp Buys 30,111 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees - Investing.com Australia
Keros Therapeutics Urges Stockholders to Vote "FOR" Director Nominees Amid Proxy Contest with ADAR1 - Nasdaq
Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of ... - Bluefield Daily Telegraph
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees - GlobeNewswire Inc.
Keros Therapeutics (KROS) Target Price Adjusted by BofA Analyst | KROS Stock News - GuruFocus
Twinbeech Capital LP Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
(KROS) Trading Signals - news.stocktradersdaily.com
3 Brilliant Stocks to Buy With $200 and Hold for 5 Years - The Globe and Mail
Janus Henderson Group PLC Sells 77,803 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
TFG Asset Management GP Ltd Acquires Shares of 103,000 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Tema Etfs LLC Makes New $565,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $37.00 Average Target Price from Analysts - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Northern Trust Corp Increases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
KROS STOCK ALERT: Levi & Korsinsky Notifies Keros Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
ADAR1 calls for Keros to release review results before vote - Investing.com Australia
ADAR1 calls for Keros to release review results before vote By Investing.com - Investing.com Canada
ADAR1 Capital ManagementISS Recommends Withholding Votes From Keros Therapeutics Directors Mary Ann Gray & Alpna Seth At Annual Meeting - marketscreener.com
KROS: Proxy Advisor Recommends Withholding Votes from Keros Directors | KROS Stock News - GuruFocus
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth - WV News
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 26,145 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Parkman Healthcare Partners LLC Sells 107,241 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):